Bivalirudin: complete guide

Bivalirudin is a 20-amino-acid synthetic peptide that directly blocks thrombin. This guide covers its structure, mechanism, labeled use in PCI, key trials and warnings.

Complete guide4 min read

Key takeaway

FDA approved bivalirudin as Angiomax on December 15, 2000. It is a 20-amino-acid direct thrombin inhibitor with a molecular weight of 2,180.3 g/mol. In the HORIZONS-AMI trial of 3,602 heart attack patients, major bleeding was 4.9% with bivalirudin versus 8.3% with heparin plus a glycoprotein IIb/IIIa inhibitor.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“FDA approved Angiomax on December 15, 2000.” (this article)
ClassHeart & blood
Body systemsHeart & vessels
Studies cited3 in this article · 3 across 1 article on Bivalirudin
Related productsResearch peptide catalog

Bivalirudin is a 20-amino-acid synthetic peptide that blocks thrombin, the enzyme at the center of blood clotting. It is a lab-designed relative of hirudin, an anticoagulant from leech saliva. This guide covers its structure, mechanism, FDA-labeled use, landmark trials and label warnings, with sources checked on November 17, 2026.

Quick answer: Bivalirudin is a prescription anticoagulant peptide. Its label covers use in patients undergoing percutaneous coronary intervention (PCI), including those with heparin-induced thrombocytopenia. It binds thrombin directly and reversibly. Bleeding is its most common adverse reaction. It has no boxed warning.

Vitrapep does not sell bivalirudin; this page is a reference summary of published research and regulatory information.

What is bivalirudin?

Bivalirudin is a direct thrombin inhibitor peptide. The label describes it as “a synthetic, 20 amino acid peptide” and “a specific and reversible direct thrombin inhibitor” (Sandoz bivalirudin label).

ChEBI, quoted in PubChem, calls it “a congener of hirudin (a naturally occurring drug found in the saliva of the medicinal leech).” It is a peptide in the simple sense: one chain of 20 amino acids made by chemical synthesis. PubChem lists the formula as C98H138N24O33 and the molecular weight as 2,180.3 g/mol (PubChem CID 16129704). Our primer on peptide synthesis explains how such chains are made.

Drugs@FDA lists the original approval of Angiomax (NDA 020873) on December 15, 2000. Sandoz is the current applicant, and the product is listed as prescription (Drugs@FDA).

Table 1

Bivalirudin: key facts

Fact Detail
Structure type Linear synthetic 20-amino-acid peptide; hirudin congener
Class Direct thrombin inhibitor (anticoagulant)
Molecular formula C98H138N24O33
Molecular weight 2,180.3 g/mol
First FDA approval December 15, 2000 (Angiomax, NDA 020873)
Brand names (US) Angiomax; many generic bivalirudin labels

How does bivalirudin work?

Thrombin is the enzyme that turns fibrinogen into fibrin, the mesh of a blood clot. Bivalirudin binds thrombin directly.

Per the label, bivalirudin “directly inhibits thrombin” by binding to its catalytic site. It also binds the “anion-binding exosite of circulating and clot-bound thrombin.” The catalytic site is the enzyme’s active center. The exosite is a separate binding area on its surface. Bivalirudin occupies both.

The block wears off on its own. The label explains that binding “is reversible as thrombin slowly cleaves the bivalirudin-Arg3-Pro4 bond.” In other words, thrombin itself slowly cuts the peptide, freeing the enzyme.

What is bivalirudin approved for?

The label states that bivalirudin is “indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (PCI).” That includes patients with heparin-induced thrombocytopenia (HIT) and heparin-induced thrombocytopenia and thrombosis syndrome (HITTS). PCI is a procedure that opens narrowed heart arteries.

What did the key trials show?

REPLACE-2. This randomized, double-blind trial enrolled 6,010 patients having urgent or elective PCI at 233 hospitals in 9 countries. It compared bivalirudin, with glycoprotein IIb/IIIa blockade only if needed, against heparin with planned IIb/IIIa blockade. The primary composite end point occurred in 9.2% versus 10.0% (odds ratio 0.92; P = .32). The prespecified noninferiority criteria were met. In-hospital major bleeding fell from 4.1% to 2.4% (P < .001) (Lincoff et al., 2003).

HORIZONS-AMI. This randomized trial enrolled 3,602 patients with ST-segment elevation heart attack undergoing primary PCI. It compared bivalirudin with heparin plus a glycoprotein IIb/IIIa inhibitor. Net adverse clinical events at 30 days were 9.2% versus 12.1% (relative risk 0.76; 95% CI 0.63 to 0.92; P = 0.005). Major bleeding was 4.9% versus 8.3% (relative risk 0.60; P < 0.001) (Stone et al., 2008; NCT00433966). Both trials were in humans.

What side effects does the label list?

The bivalirudin label has no boxed warning. Its highlights state: “Most common adverse reaction (>2%) was bleeding.” Its warnings and precautions are:

  • bleeding events;
  • acute stent thrombosis in patients with STEMI undergoing PCI; and
  • thrombotic risk with coronary artery brachytherapy.

What is bivalirudin’s regulatory status, and how is it used in research?

Bivalirudin is a prescription drug. Drugs@FDA lists Angiomax as a current prescription product from Sandoz. A DailyMed search returns 15 bivalirudin labels, including generics from Fresenius Kabi, Meitheal, Mylan and others (DailyMed).

Bivalirudin is also studied in the lab. One in vitro study added it to pooled plasma from healthy neonates, children and adults. It found “a significantly increased response to bivalirudin across all paediatric age groups as compared to adults” (Letunica et al., 2020). This used human plasma samples, not patients.

Frequently asked questions about bivalirudin

Is bivalirudin a peptide?

Yes. It is a synthetic peptide of 20 amino acids, related to hirudin from the medicinal leech.

How is bivalirudin different from heparin?

Bivalirudin binds thrombin directly, at its catalytic site and exosite, including thrombin bound in clots. Its label lists use in patients with heparin-induced thrombocytopenia.

When was bivalirudin approved?

FDA approved Angiomax on December 15, 2000.

Is bivalirudin reversible?

Yes. Thrombin slowly cleaves the peptide at its Arg3-Pro4 bond, which releases the enzyme.

What is the main side effect?

Bleeding, per the label. In trials, major bleeding was lower with bivalirudin than with heparin plus a IIb/IIIa inhibitor.

What to know now

  • Structure: synthetic 20-amino-acid peptide; hirudin congener; 2,180.3 g/mol.
  • Mechanism: binds thrombin’s catalytic site and anion-binding exosite; reversible.
  • Approval: Angiomax, December 15, 2000; anticoagulant in PCI, including HIT and HITTS.
  • Evidence: REPLACE-2 met noninferiority with less bleeding; HORIZONS-AMI cut major bleeding (4.9% vs 8.3%).
  • Safety: no boxed warning; bleeding most common; stent thrombosis warning in STEMI PCI.

What we’re watching

Label updates across the 15 bivalirudin labels on DailyMed. Follow-up studies in hospitalized children, which the 2020 in vitro study called for. Related guides: eptifibatide and enfuvirtide.

More for heart & vessels

All 13 compounds for heart & vessels

Sources: Sandoz Inc 2019, Bivalirudin prescribing information; U.S. Food and Drug Administration. Drugs@FDA: NDA 020873 (ANGIOMAX) . Retrieved November 17, Drugs@FDA: NDA 020873 (ANGIOMAX); National Center for Biotechnology Information 2026, PubChem compound summary for CID 16129704, bivalirudin; Lincoff 2003, JAMA, 289; Stone 2008, The New England Journal of Medicine, 358; Cardiovascular Research Foundation 2007, Harmonizing outcomes with revascularization and stents in acute myocardial infarction; U.S. National Library of Medicine 2026, DailyMed search results: bivalirudin; Letunica 2020, Thrombosis Research, 192. All 8 citations

Back to the research library

References

  1. Sandoz Inc. (2019). Bivalirudin prescribing information (revised 9/2019). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ce56f806-7845-429d-a1ce-c2dbf79b22eb
  2. U.S. Food and Drug Administration. Drugs@FDA: NDA 020873 (ANGIOMAX). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020873
  3. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 16129704, bivalirudin. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/16129704
  4. Lincoff, A. M., et al. (2003). Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA, 289(7), 853–863. https://doi.org/10.1001/jama.289.7.853
  5. Stone, G. W., et al. (2008). Bivalirudin during primary PCI in acute myocardial infarction. The New England Journal of Medicine, 358(21), 2218–2230. https://doi.org/10.1056/NEJMoa0708191
  6. Cardiovascular Research Foundation. (2007). Harmonizing outcomes with revascularization and stents in acute myocardial infarction (ClinicalTrials.gov ID NCT00433966). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT00433966
  7. U.S. National Library of Medicine. (2026). DailyMed search results: bivalirudin (15 labels). Retrieved November 17, 2026, from https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=bivalirudin
  8. Letunica, N., et al. (2020). Age-specific differences in the in vitro anticoagulant effect of bivalirudin in healthy neonates and children compared to adults. Thrombosis Research, 192, 167–173. https://doi.org/10.1016/j.thromres.2020.05.020